I agree clarity on revenue potential is lacking (and required) in the statement released from Unilife
There is clearly potential for significant revenue however as this is not a cheap drug:
(Wikipedia)
Cost and Market[edit source | editbeta]
A single 60 mg injection of Enoxaparin can cost $898.00 for the drug alone, as shown in a 2013 statement from a California hospital.
Annual sales approx $3.17 billion.[citation needed]
Enoxaparin is not protected by US patent due to inequitable conduct on the filing of Patent No. 5,389,618.[4]
- Forums
- ASX - By Stock
- UNS
- unilife signs long-term supply contract
unilife signs long-term supply contract, page-81
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online